These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15596636)

  • 1. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial.
    de Leeuw PW; Ruilope LM; Palmer CR; Brown MJ; Castaigne A; Mancia G; Rosenthal T; Wagener G
    Arch Intern Med; 2004 Dec 13-27; 164(22):2459-64. PubMed ID: 15596636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome.
    Ruilope LM; Kirwan BA; de Brouwer S; Danchin N; Fox KA; Wagener G; Segura J; Poole-Wilson PA; Lubsen J;
    J Hypertens; 2007 Aug; 25(8):1711-8. PubMed ID: 17620970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial.
    Ruilope LM; Zanchetti A; Julius S; McInnes GT; Segura J; Stolt P; Hua TA; Weber MA; Jamerson K;
    J Hypertens; 2007 Jul; 25(7):1473-9. PubMed ID: 17563571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Palmer CR; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    Lancet; 2000 Jul; 356(9227):366-72. PubMed ID: 10972368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nifedipine GITS and diuretics in isolated systolic hypertension--a subanalysis of the INSIGHT study.
    Mancia G; Ruilope L; Palmer C; Brown M; Castaigne A; De Leeuw P; Rosental T; Wagener G
    Blood Press; 2004; 13(5):310-5. PubMed ID: 15545155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).
    Mancia G; Brown M; Castaigne A; de Leeuw P; Palmer CR; Rosenthal T; Wagener G; Ruilope LM;
    Hypertension; 2003 Mar; 41(3):431-6. PubMed ID: 12623939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INSIGHT: international nifedipine GITS study intervention as a goal in hypertension treatment.
    Brown MJ; Castaigne A; Ruilope LM; Mancia G; Rosenthal T; de Leeuw PW; Ebner F
    J Hum Hypertens; 1996 Sep; 10 Suppl 3():S157-60. PubMed ID: 8872850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus.
    Anavekar NS; Solomon SD; McMurray JJ; Maggioni A; Rouleau JL; Califf R; White H; Kober L; Velazquez E; Pfeffer MA
    Am J Cardiol; 2008 Apr; 101(7):925-9. PubMed ID: 18359309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney function and cardiovascular disease in the hypertensive population: the ERIC-HTA study.
    Redón J; Cea-Calvo L; Lozano JV; Fernández-Pérez C; Navarro J; Bonet A; González-Esteban J;
    J Hypertens; 2006 Apr; 24(4):663-9. PubMed ID: 16531794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.
    Mahesh B; Yim B; Robson D; Pillai R; Ratnatunga C; Pigott D
    Eur J Cardiothorac Surg; 2008 Mar; 33(3):370-6. PubMed ID: 18243724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction.
    Jose P; Skali H; Anavekar N; Tomson C; Krumholz HM; Rouleau JL; Moye L; Pfeffer MA; Solomon SD
    J Am Soc Nephrol; 2006 Oct; 17(10):2886-91. PubMed ID: 16928807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global risk stratification in primary hypertension: the role of the kidney.
    Leoncini G; Ratto E; Viazzi F; Conti N; Falqui V; Parodi A; Tomolillo C; Deferrari G; Pontremoli R
    J Hypertens; 2008 Mar; 26(3):427-32. PubMed ID: 18300851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk.
    Segura J; Ruilope LM
    Fundam Clin Pharmacol; 2005 Aug; 19(4):429-37. PubMed ID: 16011729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
    Keltai M; Tonelli M; Mann JF; Sitkei E; Lewis BS; Hawken S; Mehta SR; Yusuf S;
    Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):312-8. PubMed ID: 17446813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.